# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Charles Duncan initiates coverage on Vanda Pharma (NASDAQ:VNDA) with a Overweight rating and annou...
Vanda Pharmaceuticals shares decline as Future Pak withdraws acquisition offer following Vanda's rejection and lack of resp...
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the Company's Board of Directors (the "Board"...